In re Zetia (Ezetimibe) Antitrust Litig., No. 18-md-02836 (E.D. Va.)


In the Zetia case, Faruqi & Faruqi represents a class of direct purchasers of Merck & Co.’s Zetia (ezetimibe), a drug used to treat high cholesterol.  The case alleges that Merck entered into an unlawful reverse payment settlement with generic manufacturers Glenmark Pharmaceuticals and Par Pharmaceutical in 2010 to delay generic entry until late 2016. In exchange for this delay, Merck promised Glenmark and Par not to launch an authorized generic in competition with their generic Zetia for the first 180 days their product was on the market.  The direct purchasers paid supracompetitive prices as a result of delayed generic entry and the absence of competition from an authorized generic.

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.

Details

Filed on 02/07/2018

Office

1617 JFK Boulevard, Suite 1550

19103 Philadelphia, Pennsylvania

Phone (215) 277-5770

Fax (215) 277-5771

Counsel

Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771

Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771

Finding us

Our Offices


Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331

California

10866 Wilshire Boulevard Suite 1470
Los Angeles, California 90024
(424) 256-2884
(424) 256-2885

Georgia

3975 Roswell Rd Suite A
Atlanta, Georgia 30342
(404) 847-0617
(404) 506-9534

Pennsylvania

1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania